Avista Public Acquisition Corp. II (AHPA) Bundle
Avista Public Acquisition Corp. II (AHPA), trading in the U.S. equity market and last quoted at $2.03 (change -$0.11, -0.05% as of Monday, December 15, 17:15:00 PST), was formed in 2021 as a healthcare-focused SPAC that raised $200 million in its August 2021 IPO by issuing 20 million units at $10.00 per unit, and today-headquartered in New York and listed on Nasdaq under AHPAU with plans to separate units-carries a market capitalization of approximately $176.1 million (Dec 2025) while pursuing a June 2025 proposed business combination with OmniAb designed to provide a minimum of $130 million in gross cash at closing and up to $266 million if there are no redemptions, all grounded in a mission to identify and scale healthcare companies through ethical, value-creating acquisitions, a vision to build a leading platform for healthcare innovation that improves patient outcomes, and core values of Integrity, Innovation, Collaboration, Excellence, Accountability, and Sustainability.
Avista Public Acquisition Corp. II (AHPA) - Intro
Avista Public Acquisition Corp. II (AHPA) positions itself as a purpose-built public acquisition vehicle focused on sourcing and partnering with growth-oriented private companies to deliver long-term shareholder value through strategic mergers and acquisitions. The following section outlines the company's mission, vision, and core values alongside current market context and operational priorities.- Mission: Identify and execute transformational business combinations that accelerate growth for target companies while delivering attractive risk-adjusted returns to AHPA public shareholders.
- Vision: Be a leading sponsor-driven SPAC that consistently attracts high-quality targets, leverages operational expertise to scale combined entities, and creates public-market success stories.
- Strategic focus areas:
- Sector emphasis on scalable technology-enabled and service-oriented businesses.
- Governance-driven deal diligence and a disciplined capital-allocation approach.
- Leveraging sponsor networks and operational talent to de-risk post-merger integration.
| Ticker | Market | Latest Price (USD) | Price Change (USD) | Percent Change | Latest Trade Time |
|---|---|---|---|---|---|
| AHPA | USA | 2.03 | -0.11 | -0.05% | Monday, December 15, 17:15:00 PST |
- Core values:
- Integrity - rigorous, transparent deal processes and investor communications.
- Partnership - aligning incentives with founders and management teams to drive shared outcomes.
- Discipline - conservative underwriting, clear return hurdles, and structured governance in transactions.
- Execution focus - rapid value capture through operational improvements and strategic capital deployment.
- Key performance indicators monitored by AHPA:
- Deal pipeline size and quality (targets in diligence per quarter).
- Post-combination revenue growth and margin expansion of merged entities.
- Shareholder liquidity and market price performance versus trust value and peers.
Avista Public Acquisition Corp. II (AHPA) - Overview
Avista Public Acquisition Corp. II (AHPA) is a special purpose acquisition company formed in 2021 with a strategic focus on identifying and merging with businesses in the healthcare and biopharmaceutical sectors. Headquartered in New York, New York, AHPA completed an initial public offering in August 2021 and trades on Nasdaq under the unit ticker AHPAU, with plans to list its underlying shares under AHPA upon unit separation.- IPO completed: August 2021 - 20,000,000 units issued at $10.00 per unit, gross proceeds of $200,000,000.
- Unit composition: Each unit comprised one Class A ordinary share and one‑third of a redeemable warrant.
- Headquarters: New York, New York.
- Nasdaq listing: Units listed as AHPAU; planned transition to AHPA for standalone shares post-separation.
| Metric | Value |
|---|---|
| IPO date | August 2021 |
| Units issued | 20,000,000 |
| IPO price per unit | $10.00 |
| Gross IPO proceeds | $200,000,000 |
| Nasdaq ticker (units) | AHPAU |
| Market capitalization (Dec 2025) | Approximately $176,100,000 |
| Proposed target (announced Jun 2025) | OmniAb (biopharmaceutical company) |
| Cash at closing (minimum) | $130,000,000 |
| Cash at closing (maximum, no redemptions) | Up to $266,000,000 |
- Transaction objective: Combine AHPA's public vehicle with OmniAb's technology and assets to form a public biopharma platform.
- Financing profile: Structured to deliver a base $130M in gross cash at closing, with potential incremental proceeds up to $266M if shareholder redemptions are minimal.
- Value proposition: Public-market access for OmniAb, enhanced capital resources, and strategic alignment to scale antibody discovery capabilities.
Avista Public Acquisition Corp. II (AHPA) - Mission Statement
Avista Public Acquisition Corp. II (AHPA) is focused on identifying and acquiring businesses in the healthcare sector where its capital markets access and operational expertise can accelerate scale, improve outcomes, and create shareholder value. The mission centers on disciplined deal selection, hands-on post-combination execution, regulatory compliance, and long-term stakeholder alignment.- Target sector: healthcare services, medtech, diagnostics, health IT, and specialty pharma.
- Primary objective: create sustainable equity value for public shareholders through business combinations and operational improvements.
- Execution approach: combine capital markets access with experienced management to drive strategic initiatives and measurable operational KPIs.
- Ethical business practices and strict regulatory adherence across transaction sourcing, diligence, and integration.
- Support for innovation and scalable healthcare solutions that improve patient outcomes and operational efficiency.
- Long-term relationship building with investors, target companies, clinicians, and the communities served.
| Area | Operational Focus | Quantitative Target / Benchmark |
|---|---|---|
| Capital Structure | Preserve trust value and deploy sponsor capital alongside PIPE investors | SPAC trust per public share: $10.00 (standard); target pro forma cash at close: $100M-500M (transaction-dependent) |
| Value Creation | Revenue growth via roll-ups, cross-selling, and operational improvements | Target revenue CAGR for portfolio companies: 15%-30% over 3-5 years |
| Margins & Efficiency | Operational optimization, cost synergies, improved gross and EBITDA margins | EBITDA margin improvement goal: +5-12 percentage points within 24 months post-close |
| Returns | Deliver attractive public-market returns through disciplined purchase prices and growth | Target IRR for completed combinations: 15%+ (transaction- and market-dependent) |
| Governance & Compliance | Robust board oversight, independent directors, and regulatory compliance | Full SEC and healthcare regulatory compliance at all stages; formal compliance programs implemented pre-close |
- Proprietary sourcing and industry relationships to access off-market opportunities.
- PIPE financing and flexible deal structures to maximize capital efficiency.
- Active board-level involvement and placement of operating executives to drive integration and performance.
- Time-to-close: disciplined pipeline management with a target of 6-12 months from LOI to close.
- Post-close KPI cadence: monthly operational reporting and quarterly investor updates.
- Stakeholder alignment: sponsor co-investment and equity rollover thresholds to align incentives with target management teams.
Avista Public Acquisition Corp. II (AHPA): Vision Statement
Avista Public Acquisition Corp. II (AHPA) envisions becoming a leading platform for healthcare innovation by merging with companies that have strong growth potential and innovative solutions. The vision centers on building a diversified, high-quality healthcare portfolio that accelerates patient-centric outcomes, supports research advancement, and delivers sustainable value to shareholders, employees, and partners.- Target: identify and merge with high-growth healthcare businesses-biotech, medtech, health IT, specialty pharma, and services-whose innovations can scale rapidly through capital and strategic support.
- Value creation: provide operational guidance, governance, and access to industry networks to enhance clinical development, commercialization, and reimbursement strategies.
- Impact: prioritize investments that demonstrably improve patient outcomes, advance medical research, and address unmet clinical needs.
- Sustainability: pursue growth that balances long-term commercial success with regulatory compliance, ethical standards, and environmental and social responsibility.
- Reputation: be recognized for integrity, transparency, and excellence in all transactions and stakeholder communications.
- Diversification: expand the portfolio across complementary healthcare subsectors to create a comprehensive, resilient platform.
Key operational principles that guide AHPA's vision:
- Active board-level involvement and strategic oversight for portfolio companies.
- Leveraging industry relationships to accelerate partnerships, trials, and go-to-market efforts.
- Aligning incentives between founders, management teams, and public shareholders.
| Metric | Description / Target |
|---|---|
| Initial unit price | $10.00 per unit (standard SPAC offering structure) |
| Typical SPAC lifecycle | 24 months to identify and close a business combination |
| Sponsor promote (typical) | ~20% post-combination equity (subject to deal specifics) |
| Target transaction size | $100M-$1B+ enterprise values across healthcare subsectors |
| Primary focus areas | Biotech, medtech, digital health, specialty pharma, healthcare services |
| Value levers | Capital infusion, strategic governance, commercialization support, M&A roll-ups |
Performance and governance commitments embedded in the vision:
- Transparent investor reporting and timely disclosures aligned with public market standards.
- Robust compliance frameworks to meet regulatory expectations in healthcare and securities law.
- Board composition emphasizing healthcare expertise, operational experience, and public company stewardship.
For deeper context on AHPA's background, structure, and how the company operates, see: Avista Public Acquisition Corp. II (AHPA): History, Ownership, Mission, How It Works & Makes Money
0 0 0
Avista Public Acquisition Corp. II (AHPA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.